Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Drug Metabolism & Disposition
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Drug Metabolism & Disposition

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit dmd on Facebook
  • Follow dmd on Twitter
  • Follow ASPET on LinkedIn
Research ArticleArticle

Metabolism and Excretion of a Novel Antianxiety Drug Candidate, CP-93,393, in Long Evans Rats

Differentiation of regioisomeric glucuronides by LC/MS/MS

Chandra Prakash and Victor Soliman
Drug Metabolism and Disposition November 1997, 25 (11) 1288-1297;
Chandra Prakash
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Victor Soliman
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Differentiation of regioisomeric glucuronides by LC/MS/MS

Abstract

The absorption and metabolism of a novel antianxiety drug candidate, CP-93,393, ((7S,9aS)-2-(pyrimidin-2-yl)-7-(succinimidomethyl)-octahydro-1H-pyrido[1,2-a]pyrazine) were investigated in bile-cannulated Long Evans rats after oral administration of a single 30 mg/kg base equivalent dose of14C-CP-93,393 (HCl salt). Urine, bile, plasma, and feces were collected and assayed for total radioactivity. Plasma samples were also analyzed for unchanged drug using an LC/MS/MS assay. Metabolic profiles of 14C-CP-93,393 were obtained in urine, bile, and plasma. Structural characterization of metabolites was carried out by LC/MS using a combination of full scan, product ion, constant neutral loss, and multiple reaction ion monitoring techniques. CP-93,393 was completely absorbed, as less than 1% of the administered radioactivity was recovered in the feces. The major portion of the radioactivity was recovered in bile, suggesting that the biliary route was the primary route of excretion. Total recovery of administered dose was 97.4 ± 3.3% from male rats and 85.3 ± 9.6% from female rats. Approximately 32% of the administered radioactive dose was recovered in urine of female rats, while only 20% was recovered in urine of male rats. In contrast, biliary recoveries of the radioactivity were higher for male rats (approximately 77% for males and 53% for females). MeanCmax values for the unchanged CP-93,393 and total radioactivity were significantly higher in the female rats than in the male rats. Similarly, mean AUC(0-t)values for the unchanged drug and radioactivity were also higher in female rats. These findings suggested that CP-93,393 was eliminated more rapidly in the male rats than in the female rats.

CP-93,393 and a total of 16 metabolites were identified in urine, bile, and plasma. Based on the structures of oxidative metabolites, four metabolic pathways of CP-93,393 were identified: hydroxylation at the pyrimidine ring, hydroxylation at the succinimide ring, hydroxylation alpha to the nitrogen of the piperazine ring, and hydrolysis of amide bond of the succinimide ring. The major oxidative metabolites were excreted as sulfate and/or glucuronide conjugates. The structures of regioisomeric glucuronides were established by a novel tandem mass spectrometric technique. The glucuronides were dissociated at the orifice, and the resulting aglycones were then analyzed by MS/MS studies. The identified metabolites accounted for >90% of the total radioactivity present in urine, bile, and plasma.

Footnotes

  • Send reprint requests to: Chandra Prakash, Ph. D., Department of Drug Metabolism, Central Research Division, Pfizer Inc., Groton, CT 06340.

  • This work was presented in part at the 8th North American International Society for the Study of Xenobiotics meeting, San Diego, CA (1996).

  • ↵2 J. Baxter et al. Manuscript in preparation.

  • Abbreviations used are::
    5-HT
    5-hydroxytryptamine
    GABA
    γ-aminobytyric acid
    5-OH-CP-93
    393, (7S,9aS)-2-(5-hydroxypyrimidin-2-yl)-7-(succinimidomethyl)-octahydro-1H-pyrido[1,2-a]pyrazine
    2-OH-CP-93
    393, (1S,9aS)-2-(pyrimidin-2-yl)-7-(2-hydroxysuccinimidomethyl)-octahydro-1H-pyrido[1,2-a]pyrazine
    CP-93
    558, 2-(pyrimidin-2-yl)-octahydro-1H-pyrido[1,2-a]pyrazin-7-yl)methylamine
    NPMSA
    N-(2-pyrimidin-2-yl-octahydro-pyrido[1,2-a]pyrazin-7-ylmethyl)-succinamic acid
    2-NPMHSA
    N-(2-pyrimidin-2-yl-octahydro-pyrido[1,2-a]pyrazin-7-yl-methyl)-2-hydroxysuccinamic acid
    3-NPMHSA
    N-(2-pyrimidin-2-yl-octahydro-pyrido[1,2-a]pyrazin-7-yl-methyl)-3-hydroxysuccinamic acid
    5-NHPMSA
    N-[2-(5-hydroxy-pyrimidin-2-yl)octahydro-pyrido[1,2-a]pyrazin-7-ylmethyl]succinamic acid
    LE
    Long Evans
    radio-HPLC
    HPLC with on-line radioactivity detector
    β-RAM
    radioactive monitor
    CID
    collisionally induced dissociation
    CNL
    constant neutral loss, MRM, multiple reaction monitoring
    CYP
    cytochrome P450
    • Received April 3, 1997.
    • Accepted July 15, 1997.
  • The American Society for Pharmacology and Experimental Therapeutics
View Full Text

 

DMD articles become freely available 12 months after publication, and remain freely available for 5 years. 

Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page. 

 

  • Click here for information on institutional subscriptions.
  • Click here for information on individual ASPET membership.

 

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
PreviousNext
Back to top

In this issue

Drug Metabolism and Disposition
Vol. 25, Issue 11
1 Nov 1997
  • Table of Contents
  • Index by author
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Drug Metabolism & Disposition article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Metabolism and Excretion of a Novel Antianxiety Drug Candidate, CP-93,393, in Long Evans Rats
(Your Name) has forwarded a page to you from Drug Metabolism & Disposition
(Your Name) thought you would be interested in this article in Drug Metabolism & Disposition.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleArticle

Metabolism and Excretion of a Novel Antianxiety Drug Candidate, CP-93,393, in Long Evans Rats

Chandra Prakash and Victor Soliman
Drug Metabolism and Disposition November 1, 1997, 25 (11) 1288-1297;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Research ArticleArticle

Metabolism and Excretion of a Novel Antianxiety Drug Candidate, CP-93,393, in Long Evans Rats

Chandra Prakash and Victor Soliman
Drug Metabolism and Disposition November 1, 1997, 25 (11) 1288-1297;
Reddit logo Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Metabolic enzymes in nintedanib metabolism
  • Mechanism of AO Inactivation by Hydralazine
  • Warfarin PBPK modeling with target binding
Show more Article

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About DMD
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Journal of Pharmacology and Experimental Therapeutics
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-009X (Online)

Copyright © 2023 by the American Society for Pharmacology and Experimental Therapeutics